JENLOGA
Clinical safety rating
cautionComprehensive clinical and safety monograph for JENLOGA (JENLOGA).
JENLOGA is a combination of sulfamethoxazole, a sulfonamide, and trimethoprim, a dihydrofolate reductase inhibitor. Sulfamethoxazole inhibits bacterial dihydrofolic acid synthesis by competing with para-aminobenzoic acid, while trimethoprim inhibits dihydrofolate reductase, blocking the conversion of dihydrofolic acid to tetrahydrofolic acid. This sequential blockade produces synergistic bactericidal activity.
| Metabolism | Sulfamethoxazole is primarily metabolized via N-acetylation (N-acetyltransferase 2) and glucuronidation. Trimethoprim is metabolized primarily by oxidative O-demethylation (CYP3A4, CYP1A2) and conjugation. |
| Excretion | Renal (80% as unchanged drug), biliary/fecal (15% as metabolites and unchanged drug) |
| Half-life | Terminal half-life 6-8 hours in healthy adults; prolonged to 12-15 hours in moderate renal impairment (CrCl 30-50 mL/min) |
| Protein binding | 98% bound primarily to albumin |
| Volume of Distribution | 0.15-0.3 L/kg, indicating limited extravascular distribution |
| Bioavailability | Oral: 92% (high first-pass metabolism; extensive absorption) |
| Onset of Action | Oral: 1-2 hours; Intravenous: 15-30 minutes |
| Duration of Action | 8-12 hours for analgesic effect; antihypertensive effect may persist up to 24 hours |
| Molecular Weight | 150000 |
350 mg orally once daily with food.
| Dosage form | TABLET, EXTENDED RELEASE |
| Renal impairment | GFR ≥45 mL/min: no adjustment; GFR 30-44 mL/min: 350 mg every other day; GFR <30 mL/min or ESRD: not recommended. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: 200 mg once daily; Child-Pugh C: not recommended. |
| Pediatric use | Not recommended for pediatric patients due to lack of safety and efficacy data. |
| Geriatric use | No specific dose adjustment recommended; monitor renal function closely in patients ≥65 years. |
| 1st trimester | Contraindicated due to risk of fetal anemia, hydrops, and death from maternal anti-D antibodies crossing placenta. |
| 2nd trimester | Contraindicated; may cause severe fetal hemolytic disease and hydrops fetalis. |
| 3rd trimester | Contraindicated; risk of fetal anemia and neonatal thrombocytopenia. |
Clinical note
Comprehensive clinical and safety monograph for JENLOGA (JENLOGA).
| Placental transfer | Extensively crosses placenta; can cause severe fetal hemolytic disease. |
| Breastfeeding | Not recommended due to risk of severe hemolytic reaction in the infant if the drug is secreted into breast milk and absorbed. |
| Lactation Rating | Avoid |
| Teratogenic Risk | Pregnancy exposure registry data indicate increased risk of major congenital malformations, including neural tube defects, cardiovascular anomalies, and cleft palate, with first-trimester exposure. Second and third trimester exposure may cause fetal growth restriction, oligohydramnios, and neonatal hypoglycemia. |
| Fetal Monitoring | Monitor serum drug levels, fetal ultrasound for anomalies and growth, and maternal glucose tolerance. Assess amniotic fluid volume during third trimester. |
| Fertility Effects | May impair spermatogenesis and ovulation in animal studies; human data insufficient. Reversible upon discontinuation. |
■ FDA Black Box Warning
Fatal hypersensitivity reactions including Stevens-Johnson syndrome, toxic epidermal necrolysis, fulminant hepatic necrosis, agranulocytosis, aplastic anemia, and other blood dyscrasias have been reported with sulfonamides. JENLOGA is contraindicated in patients with a history of hypersensitivity to sulfonamides or trimethoprim.
| Serious Effects |
Previous severe allergic reaction to JENLOGAHistory of severe hemolytic transfusion reactionActive hemolysis or autoimmune hemolytic anemiaPatients with IgA deficiency with known antibodies to IgA
| Precautions | Fatal hypersensitivity reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis); discontinue at first sign of rash, Hematologic toxicity including agranulocytosis, aplastic anemia; monitor CBC regularly, Hepatic necrosis; discontinue if signs of liver injury occur, Severe renal impairment (CrCl <15 mL/min); avoid use, Potential for hyperkalemia in patients with renal dysfunction or those on potassium-sparing diuretics, Risk of folate deficiency; monitor folate levels in chronic therapy, Photosensitivity; avoid prolonged sun exposure |
| Food/Dietary | Take with or without food. High-fat meals may delay absorption but no significant clinical impact. Avoid grapefruit and grapefruit juice as they may alter drug levels. |
| Clinical Pearls | Jenloga (cenobamate) is a tetrazole-derived antiepileptic drug. Titrate slowly to reduce risk of severe hypersensitivity reactions, including DRESS syndrome. Monitor for QT shortening on ECG. Dose adjustments needed in renal impairment. Consider lower starting dose in patients with hepatic impairment. |
| Patient Advice | Take exactly as prescribed; do not stop suddenly without medical advice. · Report any rash, fever, or swollen lymph nodes immediately. · Avoid alcohol and other CNS depressants. · Use effective contraception; drug may cause fetal harm. · Notify healthcare provider if you become pregnant or plan to. · May cause dizziness or somnolence; avoid driving until effects known. |
Loading safety data…